Back to results
US 8,563,541 B2Granted
Azepine inhibitors of Janus kinases
AssigneeIncyte Corporation
InventorsArgyrios G. Arvanitis, James D. Rodgers, Andrew P. Combs, Richard B. Sparks, Darius J. Robinson
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Claims44
A compound of Formula Ia, Ib, or Ic:
- or pharmaceutically acceptable salt thereof, wherein:
- D1, D2, D3, D4, D5, D6 and D7 are, independently, CR1 or N;
- E is O, S, SO, SO2, or NR2a;
- G is N or CR2b;
- Q1 and Q2 are each, independently, N or CR2c;
- W1 is absent, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, O, S, NR3, CO, COO, CONR3, SO, SO2, SONR3, SO2NR3, or NR3CONR4, wherein said C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl is optionally substituted by 1, 2 or 3 substituents independently selected from halo, OH, C1-4 alkoxy, C1-4 haloalkoxy, amino, C1-4 alkylamino and C2-8 dialkylamino;
- W2 is absent, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl is optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, NO2, OH, ═NH, ═NOH, ═NO—(C1-4 alkyl), —NR3C(O)O—(C1-4 alkyl), NR3C(O)—(C1-4 alkyl), —C(O)O—(C1-4 alkyl), C1-4 halo alkyl, C1-4 cyanoalkyl, pentahalosulfanyl, C1-4 hydroxylalkyl, C1-4 alkylthio, C1-4 haloalkylthio, C1-4 alkoxy, C1-4 haloalkoxy, amino, C1-4 alkylamino and C2-8 dialkylamino;
- W3 is absent, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, O, S, NR3, ═N—, ═N—O—, ═N—O—(C1-4 alkyl)-, O—(C1-4 alkyl), S—(C1-4 alkyl), NR3—(C1-4 alkyl), (C1-4 alkyl)-O-(C1-4 alkyl), (C1-4 alkyl)-S—(C1-4 alkyl), (C1-4 alkyl)-NR3—(C1-4 alkyl), CO, COO, C(O)—(C1-4 alkyl), C(O)O—(C1-4 alkyl), C(O)—(C1-4 alkyl)-C(O), NR3C(O)—(C1-4 alkyl), C(O)NR3—(C1-4 alkyl), NR3C(O)O—(C1-4 alkyl), NR3C(O)O, CONR3, SO, SO2, SONR3, SO2NR3, or NR3CONR4, wherein said C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl is optionally substituted by 1, 2 or 3 substituents independently selected from halo, OH, CN, C1-4 alkoxy, C1-4 haloalkoxy, amino, C1-4 alkylamino and C2-8 dialkylamino;
- W4 is H, NR3R4, CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, wherein each of said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, OH, CN, C1-4 alkoxy, ═NH, ═NOH, ═NO—(C1-4 alkyl), C1-4 haloalkyl, C1-4 haloalkoxy, pentahalosulfanyl, COOH, CONH2, COO—(C1-4 alkyl), amino, C1-4 alkylamino and C2-8 dialkylamino;
- R1 is, independently, H, halo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, NRcC(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rd, NRcC(O)ORa, S(O)Rb, S(O)NRcRd, NRcS(O)NRcRd, pentahalosulfanyl, S(O)2Rb, or S(O)2NRcRd;
- R2a is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, OH, C1-4 alkoxy, C(O)Rb, C(O)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, or S(O)2NRcRd;
- R2b and R2c are each, independently, H, halo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcC(O)NRcRd, NRcRd, NRcC(O)Rd, NRcC(O)ORa, S(O)Rb, S(O)NRcRd, NRcS(O)NRcRd, S(O)2Rb, or S(O)2NRcRd;
- R3 and R4 are each, independently, H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, arylalkyl, cycloalkylalkyl, COORa′, CORb′, SORb′, or SO2Rb′ wherein each of said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl is optionally substituted by 1, 2 or 3 substituents selected from halo, C1-4 alkyl, C1-4 haloalkyl, OH, C1-4 alkoxy, C1-4 haloalkoxy, amino, C1-4 alkylamino, C2-8 dialkylamino, aminocarbonyl, C1-4 alkylaminocarbonyl, C2-8 dialkylaminocarbonyl, CN and NO2;
- or R3 and R4 together with the N atom to which they are attached form a heterocycloalkyl group optionally substituted by 1, 2 or 3 substituents selected from halo, C1-4 alkyl, C1-4 haloalkyl, OH, C1-4 alkoxy, C1-4 haloalkoxy, amino, C1-4 alkylamino, C2-8 dialkylamino, aminocarbonyl, C1-4 alkylaminocarbonyl, and C2-8 dialkylaminocarbonyl;
- Ra and Ra′ are each, independently, H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl;
- Rb and Rb′ are each, independently, H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl;
- and
- Rc and Rd are each, independently, H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl;
- or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group;
- provided that when D7 is N, E is O or S, and G is N;
- then —W1—W2—W3—W4 is other than H.
18 more elements
Dependencies are inferred from the claim text.